COYA - Coya Therapeutics, Inc.

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 8.21

Open

$ 8.47

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 8.22 - $ 8.47

52 Week Range

$ 3.21 - $ 10.69

Volume

39,254

Average Volume

Market Cap

25.04M

Beta (5Y Monthly)

$ 0.56

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	03-19-2024	12-31-2023	10-K
3	11-08-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-10-2023	03-31-2023	10-Q
6	03-29-2023	12-31-2022	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Coya Therapeutics Q1 2024 GAAP EPS $(0.35)...
05/09/2024 21:37:18

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $...

Chardan Capital Maintains Buy on Coya Ther...
04/29/2024 12:05:15

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.

Chardan Capital Maintains Buy on Coya Ther...
03/20/2024 09:31:07

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and raises the price target from $11...

Coya Therapeutics FY23 EPS $(0.79) Vs $(4....
03/19/2024 12:19:23

Financial Results As of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5...

Coya Therapeutics Presents Biomarker Data ...
03/06/2024 13:17:03

Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines signific...

Coya Therapeutics To Present Data On Immun...
02/29/2024 13:51:50

Company to present comprehensive analysis documenting pro-inflammatory cell phenotypes and Treg dysfunction in FTD patients vs....

Coya Therapeutics To Present Novel Biomark...
02/22/2024 13:29:32

Novel biomarker data in ALS patients correlates to rate of progression and survivalCoya Therapeutics, Inc. (NASDAQ:COYA) ("...

Coya Therapeutics Issues Letter To Stockho...
02/21/2024 13:32:29

Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways i...

Greenlight Capital Adds Position In Coya T...
02/14/2024 22:13:16

Coya Therapeutics Licenses IP Rights For I...
02/13/2024 13:21:16

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 (ld IL-2) combinations, including ld ...

Coya Therapeutics Announces Pipeline Expan...
01/16/2024 13:27:00

All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dys...

Coya Therapeutics Reveals Successful Pre-I...
01/05/2024 13:05:09

Coya Therapeutics' CEO Dr. Howard Berman I...
12/13/2023 13:17:01

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company develop...

Coya Therapeutics Shares Resume Trade
12/06/2023 12:36:18

UPDATE: Dr. Reddy's To Pay COYA $4.2M Upon...
12/06/2023 12:24:30

Dr. Reddy's To Make $7.5M Upfront Payment To Coya, $4.2M Payment Upon Acceptance Of IND Application, $4.2M Upon First Patie...

Coya Therapeutics Shares To Resume Trade A...
12/06/2023 12:19:57

Coya Therapeutics Announces $26.5M Private...
12/06/2023 12:11:15

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company develop...

Dr. Reddy's To Make $7.5M Upfront Payment ...
12/06/2023 12:09:11

Coya Therapeutics And Dr. Reddy's Laborato...
12/06/2023 12:05:22

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
12/01/2023 21:31:06